Cellulite and Aesthetic Skin Improvement

Despite regular exercise and the most stringent of diets, the body can store fat in certain areas. One of the most common stubborn conditions is the appearance of cellulite. According to a 2007 study by the Millennium Research Group, nearly 90 percent of women experience some level of cellulite, and the demand for non-invasive cellulite treatments in the U.S. is expected to nearly double to over 750,000 procedures per year by 2011. Unfortunately, there is not much that rigorous exercise, diet efforts and skin care can do to minimize the appearance of cellulite. This is because the subcutaneous connective tissues are thinner in women, perpendicular to the surface, resulting in formation of large fat cell chambers. The fat cell groups herniate through the hypodermal connective tissue strands and cause the dimpling appearance of cellulite.

SANUWAVE is interested in researching how PACE’s known mechanisms to improve cell permeability, microcirculation, and the lymphatic process can be applied toward particular indications in this area.

Scars and Surgical Line Treatment

Scars can vary from a cosmetic defect to a condition that limits a person’s daily activities. Often scars are produced after a trauma to the body because during inflammation, undifferentiated collagen tissue is produced as the body attempts to simply cover and constrict an open wound. This necessary but hasty tissue formation results in scar formation, poor healing and constriction.

Microcirculation studies have determined that PACE treatment may reduce the inflammation time of the healing process and improve microcirculation. In the future, SANUWAVE hopes to show that PACE may improve the cosmetic appearance and functionality of old scars and to reduce the appearance of new scars through surgical line treatment.

Preconditioning and Reconstructive Graft and Flap Procedures

SANUWAVE will be studying the effects of PACE treatment as a technique to precondition graft and flap donation and acceptance sites prior to reconstructive surgery with the goal of improving graft or flap acceptance and healing.

The indications described above are not approved by the FDA in the U.S. This information is being provided as an educational format to base future studies upon.